Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

2014423 citationsJournal Articlebronze Open Access

Authors

Suzana Jordan · University of Zurich

Jörg H. W. Distler · Friedrich-Alexander-Universität Erlangen-Nürnberg

Britta Maurer · University of Zurich

Dörte Huscher · German Rheumatism Research Centre

Jacob M. van Laar · Utrecht University

Yannick Allanore · Délégation Paris 5

Oliver Distler

Abstract

The comparison of RTX treated versus untreated matched-control SSc patients from the EUSTAR cohort demonstrated improvement of skin fibrosis and prevention of worsening lung fibrosis, supporting the therapeutic concept of B cell inhibition in SSc.

Topics & Keywords

Systemic Sclerosis and Related Diseases Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis Autoimmune Bullous Skin Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of the Rheumatic Diseases

Volume 74, Issue 6, pp. 1188-1194

DOI: 10.1136/annrheumdis-2013-204522

Field-Weighted Citation Impact: 28.29